Objective: To determine the effectiveness of Tocilizumab in covid-19 related severe pneumonia. Introduction: COVID-19 is a global health problem causing respiratory infection. This is triggered by IL-6 characterized by raised inflammatory markers that are called cytokine release storms. Severe disease leads to hospitalization, oxygen requirement, and poor outcome. Methods: This interventional study (descriptive-analytic) was conducted in July-December 2021 at Intensive Care Unit, after ethical approval. Seventy cases of COVID-19 pneumonia with cytokine storm were included. Twenty cases have dropped either refusal to tocilizumab, pregnancy, or having contraindications to tocilizumab, leaving 50 study participants. The patient's demography, clinical, laboratory, and radiological findings, timing, and response variables of tocilizumab were recorded. The temporal readings of inflammatory markers, oxygen requirement, and clinical status were compared at admission and after tocilizumab. SPSS version 25 was used for data analysis. The chi-square test was applied with a significant p-value < 0.05. Results: There was a male predominance of 66% with a mean age of 58.6±14.8 years. The mean day of illness and hospital stay was the 8th day and 17.56 days respectively. C-reactive protein levels improved in all cases 50(100%) (p <0.0001), ferritin in 31(62%) (0.019), D dimers in 28 (56%) (p0.014), LDH in 30(60%) (p 0.02) and interleu kin-6 in 32(64%) (0.017. Survival benefit with tocilizumab was significant in patients that received it within the 10th day of illness (p 0.021). At discharge, 66.6% were off oxygen and 33.3% required domiciliary oxygen. Conclusion: COVID-19 Pneumonia with cytokine release storm bears high mortality. Significant improvement in inflammatory markers like CRP, ferritin, D-dimers and LDH shows the effectiveness of tocilizumab. Early administration within 10 days of illness has survival benefits.